Conferences and Capital The 2026 Workforce Shift

The Restart Nobody Announced

Programmes come back online well before anyone publishes a press release. Budgets reopen before requisitions appear. Leadership changes circulate privately long before they are confirmed.

That timing gap runs through Lisamarie O'Brien's section of our latest report, the Global Life Sciences Workforce Outlook. Lisamarie works in business development across our US desk, and she reads the market from the place where most early signals surface, which is the conversation around a conference rather than the session inside it.

Her starting point is that 2025 never produced a clean recovery. Regulatory and policy uncertainty stalled the early momentum, capital slowed, sponsors and CROs reduced headcount and trials paused. The market reset rather than collapsed, and by late summer the inflection was visible. Trials came off hold. Sites started expanding. Hiring returned in a shape the industry had not used before.

What "Responsible Go" Looks Like in Hiring

Organizations have stopped rebuilding teams and hiring ahead of growth. They are bringing people in to deliver against specific milestones and immediate execution needs.

"There is hiring movement right now, and it's intentional. It's closely tied to specific milestones, and the roles are geared towards people who have a direct impact on execution and revenue."

That pressure has changed workforce design as much as it has changed headcount. Rather than committing to larger permanent teams, many organisations are looking for ways to access execution capacity without locking in fixed costs, then scaling that capacity as trials restart, pause or expand. Contract and consulting demand has grown in strategic importance as a result. Flexible staffing now sits inside the workforce plan rather than beside it as a contingency.

"Flexibility and speed are going to be critical in 2026, or you're not going to be able to compete."

Sites and Site Networks: Where Growth Is Returning First

The clearest signal is concentrated at site and site network level, which follows logically from where strategy becomes operational reality. When programmes restart, the volume and the complexity arrive there first. The roles showing the strongest growth reflect that: principal investigators and clinical research coordinators carrying delivery, business development strengthening trial pipelines, senior clinical operations leadership holding consistency across expanding networks, plus quality and regulatory support as those networks scale.

Site leaders describe a control problem as much as a hiring one. Absorb rising trial demand efficiently and you capture disproportionate growth. Stay operationally constrained and you become a bottleneck in someone else's restart.

The Other Party in the Room

Investors are no longer observing from a distance. Delegate lists have changed and so has the level of influence over who runs a portfolio company.

"You can't go to a conference nowadays where the delegate list doesn't have a third of it as investors, and that was never the case before."

The logic is straightforward. Leadership and execution shape revenue outcomes, so investors are paying closer attention to the people running their assets. Hiring in those environments tends to concentrate on leverage roles that strengthen delivery across several assets at once, which makes the distinction between a coordinator at a sponsor, a CRO and a site network far more consequential than the job title suggests.

Candidates, meanwhile, have moved in a different direction to the market. After a difficult year of layoffs and prolonged uncertainty, many are weighing leadership quality, culture and purpose more heavily than compensation. Employers want immediate impact from leaner teams with less capacity to train. That leaves a narrower window in which both sides can be satisfied, and the organisations reading the signals early are the ones moving into it first.

Lisamarie's full analysis, alongside perspectives from across our specialist teams, sits in the Global Life Sciences Workforce Outlook.

Read the full Global Life Sciences Workforce Outlook today!